Details

Autor(en) / Beteiligte

• Tolcher, Anthony W.
• LoRusso, Patricia
• Arzt, Jennifer
• Busman, Todd A.
• Lian, Guinan
• Rudersdorf, Niki S.
• Vanderwal, Carol Ann
• Waring, Jeffrey F.
• Yang, Jianning
• Holen, Kyle D.
• Rosen, Lee S.

Titel

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study

Ist Teil von

• Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.1041-1049

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2015

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Purpose The oral Bcl-2 inhibitor navitoclax demonstrated activity in solid and hematologic malignancies as monotherapy and in combination with other cytotoxic agents in preclinical and early clinical studies. We evaluated the safety, pharmacokinetics (PK), and antitumor activity of navitoclax plus irinotecan. Methods In this multicenter, open-label, phase 1 dose escalation study, adults with advanced solid tumors received navitoclax (starting dose 150 mg/day) in combination with 1 of 2 irinotecan schedules during a 21-day cycle: a once-every-3-week regimen (Q3W 180, 250, or 350 mg/m 2 ) or a once-weekly regimen (QW 75 or 100 mg/m 2 ). Enrollment occurred until a maximum tolerated dose (MTD) and/or recommended phase 2 dose (RPTD) was reached. Results All patients (Q3W, n  = 14; QW, n  = 17) were evaluable for safety, PK, and efficacy. The most common adverse event in both groups was diarrhea (Q3W 92.9 %; QW 76.5 %), which was the most frequent grade 3/grade 4 adverse event (Q3W 42.9 %; QW 29.4 %). The study was amended to exclude 4 UGT1A1*28 7/7 homozygous patients due to frequent irinotecan-related grade 3/grade 4 diarrhea and/or febrile neutropenia. No apparent PK interactions between navitoclax and irinotecan were observed. The MTD of the combination was exceeded in the Q3W group at the lowest dose administered. In the QW group, the MTD and RPTD for navitoclax were 150 mg when combined with irinotecan 75 mg/m 2 . One patient in each group achieved a partial response. Conclusion The RPTD of navitoclax in combination with irinotecan 75 mg/m 2 QW during a 21-day cycle was 150 mg in these heavily pretreated patients.